We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Technology Quantitatively Analyzes Alzheimer's Biomarkers Using MR and PET Images

By HospiMedica International staff writers
Posted on 21 Jul 2023

A novel treatment for Alzheimer's disease utilizes an anti-amyloid antibody drug to reduce amyloid beta proteins in the brain. More...

However, a common side effect, ARIA (Amyloid-Related Imaging Abnormalities), often appears in brain scans of patients using the drug. Therefore, careful monitoring and management of ARIA is crucial when prescribing anti-amyloid antibody drugs. Now, new cutting-edge brain imaging solutions for Alzheimer's disease treatment can enable the analysis of ARIA, thereby improving efficacy and outcomes.

Neurophet (Seoul, South Korea), an artificial intelligence (AI) solution company specializing in brain diseases, has developed a new technology to examine ARIA-E (edema) typically detected by T2-FLAIR, an MRI sequence, and ARIA-H (hemorrhages), primarily identified by GRE or SWI. An amyloid-PET scan is necessary to observe cortical amyloid beta deposition. Neurophet’s advanced technology predicts amyloid positivity through MR images before conducting amyloid-PET scans. The use of MR images for predicting amyloid positivity could provide a cost-effective solution for clinical trials and prognosis monitoring of Alzheimer's disease treatment, given that amyloid-PET scans are costly and their use and reimbursement are severely restricted. Moreover, PET scans are not universally accessible due to the limited availability of PET scanners.

At the recent Alzheimer's Association International Conference (AAIC) 2023, Neurophet showcased its cutting-edge brain imaging analysis technology, which can be applied in clinical trials and the prescription of new Alzheimer's disease drugs. The company's Neurophet AQUA software, a brain MRI analysis tool, analyzes brain atrophy observed in neurodegenerative diseases like Alzheimer's. Another product, the Neurophet SCALE PET software, quantitatively assesses Alzheimer's disease biomarkers using MR and PET images. It provides quantitative measurement of cortical amyloid beta deposition, a known causative agent of Alzheimer's disease. Neurophet is investing in research and development of analysis technology for ARIA side effects and aims to bring the products to market along with the launch of new Alzheimer's disease treatments.

"Neurophet's major products and technologies are expected to be very useful in the process of clinical trials, diagnosis, side effect monitoring and prognosis observation of Alzheimer's disease treatment." said CEO Jake Junkil Been of Neurophet. "We are going all out to develop solutions related to Alzheimer's disease treatment to preemptively target the high-growth Alzheimer's disease treatment market."

Related Links:
Neurophet 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: Shutterstock

AI-Derived Heart Age Linked to Cardiovascular and Dementia-Related Mortality

Cardiovascular disease is increasingly associated with dementia-related mortality and other forms of age-related decline. Identifying people with greater long-term vulnerability before severe outcomes... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.